Janux Therapeutics, Inc.

What they do

Janux applies proprietary TRACTr (Tumor Activated T Cell Engager), TRACIr (Tumor Activated Immunomodulator), and ARM (Adaptive Immune Response Modulator) platforms to build novel immunotherapies. Its lead candidates are JANX007 and JANX014, PSMA-targeted TRACTrs in Phase 1 for metastatic castration-resistant prostate cancer, plus JANX008, an EGFR TRACTr in Phase 1 across solid tumors. JANX011, a CD19-targeted ARM, is in a Phase 1 healthy volunteer study for autoimmune diseases, and JANX013, a PSMA-targeted CD28 costimulatory TRACIr, is pending clinical initiation. The company funds operations through equity financings and collaborations with Merck and Bristol-Myers Squibb; product candidates other than JANX007, JANX011, and JANX014 remain preclinical.

Revenue drivers

• Collaboration revenue — Historically the primary recurring revenue source, derived from collaboration agreements with Merck Sharp & Dohme and Bristol-Myers Squibb; annual revenue ranged from $3.6M in 2021 to $10.6M in 2024 before easing to $10.0M in 2025. The company states it has never generated any revenue from product sales.
• JANX007 (PSMA-TRACTr) — Lead prostate cancer program in Phase 1/1b for mCRPC; no revenue today, but the most advanced asset and the focus of ongoing taxane-naive monotherapy and darolutamide combination expansion cohorts.
• JANX014 and JANX013 (PSMA programs) — Earlier-stage prostate cancer assets with no revenue; JANX014, a double-masked PSMA TRACTr, entered clinical evaluation in April 2026, and JANX013 is planned for clinical development in the second half of 2026.
• JANX011 (CD19-ARM) — Pre-revenue autoimmune disease program in Phase 1 healthy volunteers since February 2026; the first ARM candidate to enter the clinic and not currently a revenue source.

Recent performance

Second quarter 2026 net loss was $22.0 million, narrower than the $33.9 million loss in the comparable 2025 period. Research and development expenses were $31.0 million versus $34.7 million a year earlier, while general and administrative expenses were $11.0 million versus $10.5 million. For the six months ended June 30, 2026, net loss was $46.3 million compared with $57.4 million in the first half of 2025, and the accumulated deficit stood at $397.7 million as of June 30, 2026. Cash, cash equivalents and short-term investments were $970.9 million at quarter-end versus $966.6 million on December 31, 2025. Full-year 2025 results included a $113.6 million net loss and $10.0 million of revenue, with operating cash use of $82.2 million.

Strategy

Management is prioritizing clinical execution across the prostate cancer portfolio, with JANX007 Phase 1b enrollment continuing in taxane-naive monotherapy and darolutamide combination cohorts, and JANX014 enrolling in a Phase 1 mCRPC study. JANX011 is advancing through a Phase 1 healthy volunteer study as the company's first clinical ARM program for autoimmune disease, and JANX013 remains on track for clinical initiation in the second half of 2026. The company also continues to generate additional TRACTr, TRACIr and ARM programs for potential future development. The stated $970.9 million cash position is intended to fund advancement of multiple clinical programs.

Risks

• No product revenue — Janux has never generated product sales and all candidates other than JANX007, JANX011, and JANX014 are preclinical, so revenue depends on collaboration receipts and future approvals that may not occur.
• Substantial and growing losses — Net loss was $113.6 million in 2025 and $46.3 million in the first half of 2026, with an accumulated deficit of $397.7 million as of June 30, 2026.
• Clinical trial risk — JANX007, JANX008, JANX011 and JANX014 are all in Phase 1, and JANX013 has not yet entered the clinic, so safety or efficacy results could delay or halt development.
• Reliance on equity and collaboration capital — Operations have been funded primarily through convertible notes, preferred stock, IPO proceeds, and public offerings, plus Merck and Bristol-Myers Squibb collaborations, making future financing or partnership terms important to funding needs.

Outlook

Management expects initial clinical data from the JANX011 Phase 1 healthy volunteer study in the second half of 2026 and clinical initiation of JANX013 in the same period. Additional JANX007 clinical data is expected to be announced at a future medical congress in the first half of 2027. The company also states it continues to advance additional TRACTr, TRACIr and ARM programs for potential future development.